期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

分子靶向治疗在HER2阳性乳腺癌中的临床应用策略 被引量：1

Clinical application of molecular targeted therapy in HER2-positive breast cancer
下载PDF
导出
摘要 人表皮生长因子受体2(HER2)阳性乳腺癌进展快,预后差。但随着曲妥珠单抗等分子靶向药物的临床应用,显著改善了HER2阳性乳腺癌患者的疗效。本文总结了HER2标准检测和分子靶向药物在HER2阳性乳腺癌治疗中的临床应用策略及治疗进展。 The progression of the human epidermal growth factor receptor 2 （HER2）-positive breast cancer is rapid with poor prognosis. However, with clinical application of molecular targeted drugs such as trastuzumab and so on, their efifcacy in patients with HER2-positive breast cancer has been signiifcantly improved. The strategies and treatment progress for clinical application of the standard test of HER2 and molecular targeted drugs in the treatment of HER2-positive breast cancer are summarized.
作者 王红鹰
机构地区 复旦大学附属华山医院普外科
出处 《上海医药》 CAS 2015年第21期3-5,31,共4页 Shanghai Medical & Pharmaceutical Journal
关键词 乳腺癌 分子靶向治疗 人表皮生长因子受体2 breast cancer molecular targeted therapy HER2
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献13

  • 1WolffAC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update[J]. J Clin Oncol, 2013, 31(31): 3997-4013.
  • 2乳腺癌HER2检测指南（2014版）[J].中华病理学杂志,2014,43(4):262-267. 被引量：295
  • 3Baselga J, Cort6s J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer[J]. N Engl J Med, 2012, 366(2): 109-119.
  • 4Kaufman B, Mackey JR, Clemens MR, et al. Anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TANDEM study [J]. J Clin Oncol, 2009, 27(33): 5529-5537.
  • 5Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer[J]. N Engl J Med, 2006, 355(26): 2733-2743.
  • 6Verma S, Miles D, Giannil L, et al. Trastuzumab emtansine for HER-2-positive advanced breast cancer[J]. N Engl J Med, 2012, 367(19): 1783-1791.
  • 7Perez EA, Romond EH, Suman V J, et al. Four-year follow- up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31 [J]. J Clin Oncol, 2011, 29(25): 3366-3373.
  • 8Goldhirsch A,Gelber RD,Piccart-Gebhart M J, et al. 2 yearsversus 1 year of adjuvant trastuzumab for HER-2-positive breast cancer(HERA):an open-label, randomised controlled trial[J]. Lancet, 2013, 382(9897): 1021-1028.
  • 9Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER-2- positive early breast cancer (PHARE): a randomised phase 3 trial[J]. Lancet Oncol, 2013, 14(8): 741-748.
  • 10Piccart-Gebhart M J, Holmes AP, Basega J, et al. First results from the phase lII ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T-*L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC)[EB/OL]. [2015- 06-20]. http: //rneetinglibrary.asco.org/content/128258-144.

二级参考文献20

  • 1张瑰红,施达仁,梁晓曼,侯景辉,康苏娅,朱卫东,李晓兵,邵云,陈丽荣,周燕.显色原位杂交和免疫组织化学检测乳腺癌HER2/neu基因状况和蛋白表达的对照性研究[J].中华病理学杂志,2006,35(10):580-583. 被引量：29
  • 2<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量：164
  • 3Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer [ J]. J Clin Oncol, 2007, 25 (33) :5287-5312.
  • 4Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Chnical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[ Jl. J Clin Oncol, 2007, 25 ( 1 ) : 118- 145.
  • 5Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth faetor reeeptor 2 testing in breast eaneer: American Society of Clinical Oneology/College of American Pathologists clinical practice guideline update[J]. J Clin Oneol, 2013, 31 (31) :3997-4013.
  • 6Hanna WM, Kwok K. Chromogenic in-situ hybridization:a viable ahernative to fluorescence in-situ hybridization in the HER2 testing algorithm[J]. Mod Pathol, 2006, 19(4) :481-487.
  • 7Park K, Han S, Kim JY, et al. Silver-enhanced in situ hybridization as an alternative to fluorescence in situ hybridization for assaying HER2 amplification in clinical breast cancer [ J ]. J Breast Cancer, 2011, 14(4) :276-282.
  • 8Haines GK 3rd, Wiley E, Susnik B, et al. HER2 in well differentiated breast cancer: is testing necessary? [ J ]. Breast Cancer Res Treat, 2008, 112(3) :551-556.
  • 9Zhu X, Lu Y, Lu H, et al. Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer [J]. Hum Pathol, 2011,42(10) : 1499-1504.
  • 10Marchio C, Lambros MB, Gugliotta P, et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer.9 A fluorescence in situ hybridization and microarray-based CGH analysis[ J]. J Pathol, 2009, 219( 1 ) : 16-24.

共引文献294

同被引文献3

引证文献1

二级引证文献1

上海医药
2015年 第21期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部